Horizon Pharma reports Q1 adjusted EPS 30c, consensus 12c Reports Q1 revenue $280.4M, consensus $238.35M."We are off to a strong start this year, achieving double-digit net sales growth in the first quarter and raising our full-year outlook, indicative of our continued strong commercial execution," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon. "In addition, during the quarter we announced dramatic teprotumumab Phase 3 trial results that support a mid-year U.S. regulatory submission, a key milestone in our evolution to a development-focused rare disease biopharma company. We are one step closer to delivering the first FDA-approved treatment to people living with active thyroid eye disease. Last week our shareholders approved changing the name of the Company to Horizon Therapeutics plc. Our new name more clearly reflects both our long-term strategy to develop and commercialize innovative new medicines addressing rare diseases with very few effective options as well as the fact that our work with patients, caregivers, physicians and communities goes well beyond our medicines."Read more at: (source)https://thefly.com/landingPage...Tiger's Take: $HZNP On our trading list, a biotech with good potential. Horizon just reported very nice earnings and could be considered a good long term health-care/drug stock. $HZNP, Horizon Therapeutics Public Limited Company / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.